Biotheranostics, Inc., pivotal data on the Breast Cancer Index® (BCI) test featured In "Annals of Oncology" journal

Biotheranostics, Inc.’ pivotal data on the Breast Cancer Index® (BCI) test that further validates its ability to accurately predict which women with early-stage, hormone receptor positive (HR+) breast cancer will benefit from extended endocrine therapy was featured on the cover of “Annals of Oncology” Journal.

Findings from the Translational-aTTom study (Trans-aTTom) led by an international team of cancer researchers strengthen BCI clinical evidence as a predictive biomarker and highlight its utility in helping physicians determine 5 vs. 10-year endocrine treatment plans for their patients.

To access click here